8 November 2021 - - US-based pharmaceutical company KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) presented data at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, the company said.

Data presentations included an oral presentation and poster presentation on Phase 2 data for KVD900, KalVista's lead program for oral on-demand treatment of hereditary angioedema attacks.

KVD900 was rapidly absorbed, with measurable concentrations detected within 15 minutes. Plasma levels reached peak concentration within 1 hour of administration.

Median time to symptom improvement was significantly shorter with KVD900 than with placebo (1.6 vs 9.0 hours, p